Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2025 09:00 ET | Source: Research and Markets

B7-H3-Targeted Immunotherapy Competitor Analysis Report 2025: More Than 15 Product Candidates are in Clinical Development, with Several Already in Clinical Phase III

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "B7-H3-Targeted Immunotherapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 27, 2025 08:56 ET | Source: Research and Markets

Folate Receptor Alpha (FRa) Targeted Therapy Competitor Analysis Report 2025: Next Generation Cell Therapy Modalities and Radiopharmaceuticals are Advancing in the Pipeline

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive...
November 27, 2025 08:45 ET | Source: Research and Markets

NaPi2b-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of NaPi2b-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 24, 2025 04:06 ET | Source: Research and Markets

Rare NRG1 Fusion Market Research Report 2025-2035 | Growth Accelerates on Rising Cancer Awareness and Advances in Molecular Testing and Targeted Therapies

Dublin, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The "Rare NRG1 Fusion Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been...
November 19, 2025 09:54 ET | Source: Research and Markets

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Research and Forecast Report 2025-2035: CD123-Targeted Therapies Emerge as the Leading Opportunity, Driven by ADCs, CAR-T, Bispecific Development

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Blastic Plasmacytoid Dendritic Cell Neoplasm Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast,...
October 31, 2025 09:00 ET | Source: Xcellon Biologics

IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies

IntoCell and Xcellon Biologics partner to expand ADC development access, combining IntoCell's OHPAS payload-linker platform with Xcellon's CDMO expertise.
October 13, 2025 07:59 ET | Source: Research and Markets

Conjugated Drugs (XDCs) in Oncology Market Intelligence Tool Launched – Covering 2,500+ Pipeline Drugs and 1,300+ Funding Rounds

Dublin, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Market of Conjugated Drugs (XDCs) in Oncology with Confidence" directory has been added to ...
September 03, 2025 16:07 ET | Source: Radiance BioPharma

Radiance Biopharma Signs Exclusive License For ‘First In Class’ c-Met/EGFR Targeted Nano Antibody ADC

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or "Company"), a clinical-stage biotechnology company, announced that it has signed an Exclusive License Agreement...
August 26, 2025 04:11 ET | Source: Research and Markets

Bispecific Antibody Drug Conjugates Clinical Trials and Competitive Landscape Report 2025 | Over 100 Bispecific ADCs Progressing in Clinical Trials

Dublin, Aug. 26, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape & Market Opportunity Insight 2025" report has...
August 15, 2025 08:24 ET | Source: Research and Markets

Antibody Drug Conjugates Market Analysis Report 2025 | ADCs Set for Growth Amid Regulatory Evolutions and Technological Advances

Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates: Market Share, and Growth Analysis by Product Type (Monoclonal Antibodies, Small Molecule Drugs), Application, End User,...